Clinical Trials Logo

Filter by:
NCT ID: NCT02385162 Withdrawn - Clinical trials for Glycogen Storage Disease Type II

Biomarker for Glycogen Storage Diseases (BioGlycogen)

BioGlycogen
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Glycogen Storage Diseases from plasma. Testing for clinical robustness, specificity and long-term stability of the biomarker.

NCT ID: NCT02383641 Withdrawn - Clinical trials for Cholesterol Ester Storage Disease

Biomarker for Wolman Disease (BioWolman)

BioWolman
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Wolman disease blood (plasma)

NCT ID: NCT02298712 Withdrawn - Clinical trials for Metabolism, Inborn Errors

Biomarker for Hurler Disease (BioHurler)

BioHurler
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Hurler disease from plasma. Testing for clinical robustness, specificity and long-term stability of the biomarker.

NCT ID: NCT02298699 Withdrawn - Developmental Delay Clinical Trials

Biomarker for Sly Disease (MPS VII) (BioSly)

BioSly
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)

NCT ID: NCT02298686 Withdrawn - Developmental Delay Clinical Trials

Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)

BioSanfilippo
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of Sanfilippo Disease Type A-B-C-D from blood (plasma)

NCT ID: NCT02298673 Withdrawn - Clinical trials for Skeletal Abnormalities

Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)

BioML
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Mucolipidosis Disorder type I,II,III or IV from blood (plasma)

NCT ID: NCT02298647 Withdrawn - Seizures Clinical Trials

Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

BioGM1/BioGM2
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of GM1/GM2 from blood

NCT ID: NCT01668472 Withdrawn - Clinical trials for Pregnant Woman With Premature Rupture of Amnion Membranes

A Comparison of Rapid Immunoassay Tests for the Detection of Ruptured Membranes

Start date: August 2012
Phase: N/A
Study type: Observational

Specific objectives include analysis of performance of ROM Plus® in diagnosing ROM, as compared to Amnisure® and the conventional clinical assessment confirmed by a thorough chart review after delivery.

NCT ID: NCT01536327 Withdrawn - Muscle Weakness Clinical Trials

Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease

BioMeta
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Metachromatic Leu-kodystrophy disease from blood (plasma)

NCT ID: NCT01458613 Withdrawn - Lung Diseases Clinical Trials

Biomarker for Maroteaux-Lamy Disease (BioMaroteaux)

BioMaroteaux
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Maroteaux-Lamy disease from blood